Healthy Skepticism Library item: 14815
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: media release
Sales Through Retail Pharmacies (Twelve months to October 2008*)
2008 Dec
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Retail_Drug_Monitor_December_2008.pdf
Full text:
NORTH AMERICA $225.5 billion up 1%
U.S.A. $208.4 billion up 1%
CANADA $17.0 billion up 6%
EUROPE (TOP 5) $116.4 billion up 2%
GERMANY $35.7 billion up 4%
FRANCE $31.1 billion up 1%
UK $16.4 billion down 2%
ITALY $17.5 billion up 1%
SPAIN $15.5 billion up 5%
JAPAN (including hospitals) $66.4 billion up 4%
LATIN AMERICA (TOP 3) $24.7 billion up 10%
BRAZIL $12.7 billion up 11%
MEXICO $8.8 billion up 3%
ARGENTINA $3.1 billion up 23%
AUSTRALIA/NZ $8.1 billion up 11%
The top 5 therapy classes at ATC3 level in the 12 months to October 2008
were:
1. C10A – Cholesterol & trigly. regulators
2. A2B – Antiulcerants
3. N6A – Antidepressants & mood stabilisers
4. N5A – Antipsychotics
5. N3A – Anti-epileptics
The top 5 products in the 12 months to October 2008 were:
1. Lipitor
2. Plavix
3. Nexium
4. Seretide/Advair
5. Enbrel
The top 5 corporations in the 12 months to October 2008 were:
1. Pfizer
2. GlaxoSmithKline
3. AstraZeneca
4. Novartis
5. Sanofi-Aventis
